Answers are grounded in this paper and cite their sources.
Kidney disease is a rapidly growing global health concern, tightly linked to cardiovascular and metabolic disease within the recently defined cardiovascular-kidney-metabolic (CKM) syndrome. Routine clinical assessment of kidney function primarily relies on creatinine-based estimated glomerular filtration rates (eGFRcr) which can be affected by non-renal factors and declines only after substantial kidney damage. Using data from the MetaCardis study (N=1,723), we derived metabolomic kidney function gaps (mKFGs)-the difference between metabolome-predicted eGFRcr and measured eGFRcr. A physiology-guided feature-selection strategy - anchored on three cardiometabolic markers (haemoglobin, albumin and the Neutrophil-to-Lymphocyte Ratio) that associate with mKFGs but not with eGFRcr - yielded compact sex-stratified metabolite panels (40-98 out of 1,514 metabolites) that tracked cardiovascular-kidney-metabolic risk. Machine-Learning models revealed distinct metabolic signatures, including biomarkers of meat consumption and androgens, highlighting potential sex-specific pathways linked to CKM health. External validation in the general-population Canadian Longitudinal Study on Aging (N=9,958) and German Chronic Kidney Disease Study (N=5,113) cohorts revealed that mKFGs added incremental predictive value for future CKM events and all-cause mortality beyond eGFRcr and established risk equations. Our findings open new avenues for personalised risk stratification for CKM disease progression and targeted interventions based on metabolically defined kidney health.
No takes yet. Share an insight, caveat, or question.
Andrikopoulos et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: